Clinical Trials
26 trialsNCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06712316 2026-05-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
Phase 2/3 Recruiting
NCT07063745 2026-05-18
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT05506943 2026-05-07
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics
Phase 2/3 Active not recruiting
NCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07554456 2026-04-28
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT03315364 2026-04-01
OPTIMAL
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3 Active not recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT06321068 2025-08-14
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
Phase 2/3 Terminated
NCT05002127 2025-08-07
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology Inc.
Phase 2/3 Active not recruiting
NCT06123884 2025-02-10
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Bio-Thera Solutions
Phase 2/3 Recruiting
NCT04499924 2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3 Completed
NCT05747794 2024-12-17
AIPAC-003
Immutep S.A.S.
Phase 2/3 Active not recruiting
NCT03721744 2024-04-03
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
1Globe Biomedical Co., Ltd.
Phase 2/3 Unknown
NCT06221748 2024-04-03
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
Phase 2/3 Recruiting
NCT04864782 2024-01-12
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Terminated
NCT05427383 2023-12-19
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
Phase 2/3 Recruiting
NCT04435652 2020-06-17
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT02651610 2017-07-11
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
Phase 2/3 Withdrawn
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT00473889 2015-07-03
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00003880 2015-04-16
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated
NCT00337532 2010-02-04
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
Bristol-Myers Squibb
Phase 2/3 Completed